Oral administration of peptides and proteins: Nanoparticles and cyclodextrins as biocompatible delivery systems

Nanomedicine

Volumn 2, Issue 2, 2007, Pages 183-202

  Soares, Ana Francisca ^a   Carvalho, Rui de Albuquerque ^b   Veiga, Francisco ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Absorption enhancement; Amphiphilic cyclodextrins; Controlled release; Cyclodextrins; Enzymatic protection; Nanoparticles; Nanoprecipitation; Oral drug delivery; Peptides and proteins; Targeting

Indexed keywords

CARBOPLATIN; CHLORHEXIDINE; CHYMOTRYPSIN A; CYCLODEXTRIN DERIVATIVE; FUROSEMIDE; HYDROCORTISONE; INSULIN; MACROGOL; NANOCAPSULE; NANOPARTICLE; PEPTIDE; POLYMER; PROGESTERONE; PROTEIN; SAQUINAVIR; TRICLOSAN; ZOLPIDEM;

BIOCOMPATIBILITY; CARCINOMA CELL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; ENZYME ACTIVITY; HUMAN; NANOPHARMACEUTICS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN TRANSPORT; REVIEW; SAFETY; TOXICITY TESTING;

ADMINISTRATION, ORAL; BIOCOMPATIBLE MATERIALS; CYCLODEXTRINS; DRUG CARRIERS; NANOMEDICINE; NANOPARTICLES; PEPTIDES; PROTEINS; VEHICLES;

EID: 34249782272     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.2.2.183     Document Type: Review

References (133)

1. Allémann E, Leroux J-C, Gurny R: Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Deliv. Rev. 34(1-2), 171-189 (1998).
2. Aungst BJ, Saitoh H, Burcham DL, Huang S-M, Mousa SA, Hussain MA: Enhancement of the intestinal absorption of peptides and nonpeptides. J. Control. Release 41(1-2), 19-31 (1996).
3. Florence AT, Hillery AM, Hussain N, Jani PU: Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J. Control. Release 36(1-2). 39-46 (1995).
4. Haeberlin B, Gengenbacher T, Meinzer A, Fricker G: Cyclodextrins - useful excipients for oral peptide administration? Int. J. Pharm. 137(1), 103-110 (1996).
5. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T: Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50(1), 147-160 (2000).
6. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ: Chitosan-PEG nanocapsules as new carriers for oral peptide delivery: effect of chitosan pegylation degree. J. Control. Release 111 (3), 299-308 (2006).
7. Sakuma S, Hayashi M, Akashi M: Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv. Drug Deliv. Rev. 47(1), 21-37 (2001).
8. Salamat-Miller N, Johnston TP: Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294(1-2), 201-216 (2005).
9. Sarciaux JM, Acar L, Sado PA: Using microemulsion formulations for oral drug delivery of therapeutic peptides. Int. J. Pharm. 120(2), 127-136 (1995).
10. Still JG: Development of oral insulin: progress and current status. Diabetes Metab. Res. Rev. 18(S1), S29-S37 (2002).
11. Nakamura K, Murray RJ. Joseph JI, Peppas NA, Morishita M, Lowman AM: Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on insulin delivery characteristics. J. Control. Release 95(3), 589-599 (2004).
12. TenHoor CN, Dressman JB: Oral absorption of peptides and proteins. Stp Pharma. Sci. 2(4), 301-312 (1992).
13. Cheng J, Teply BA, Jeong SY et al.: Magnetically responsive polymeric microparticles for oral delivery of protein drugs. Pharm. Res. 23(3), 557-564 (2006).
14. Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78(3), 260-277 (2005).
15. Pinto Reis C, Neufeld RJ, Ribeiro AJ. Veiga F: Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2(2), 53-65 (2006).
16. Pauletti GM, Gangwar S, Knipp GT et al.: Structural requirements for intestinal absorption of peptide drugs. J. Control. Release 41 (1-2), 3-17 (1996).
17. Uekama K, Hirayama F, Irie T: Cyclodextrin drug carrier systems. Chem. Rev. 98(5), 2045-2076 (1998).
18. Bilati U, Allemann E, Doelker E: Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur. J. Pharm. Biopharm. 59(3), 375-388 (2005).
19. Wang W: Protein aggregation and its Inhibition in biopharmaceutics. Int. J. Pharm. 289(1-2), 1-30 (2005).
20. Tavornvipas S, Tajiri S, Hirayama F, Arima H. Uekama K: Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm. Res. 21(12). 2369-2376 (2004).
21. Langguth P, Bohner V, Heizmann J et al.: The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Release 46(1-2), 39-57 (1997).
22. Fjellestad-Paulsen A, Soderberg-Ahlm C, Lundin S: Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract. Peptides 16(6), 1141-1147 (1995).
23. Lundin S, Pantzar N, Broeders A, Ohlin M, Westrom BR: Differences in transport rate of oxytocin and vasopressin analogues across proximal and distal isolated segments of the small intestine of the rat. Pharm. Res. 8(10), 1274-1280 (1991).
24. Lang VB, Langguth P. Ottiger C et al.: Structure-permeation relations of metenkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers. J. Pharm. Sci. 86(7), 846-853 (1997).
25. Mizuma T. Koyanagi A, Awazu S: Intestinal transport and metabolism of glucose-conjugated kyotorphin and cyclic kyotorphin: metabolic degradation is crucial to intestinal absorption of peptide drugs. Biochim. Biophys. Actav. 1475(1), 90-98 (2000).
26. Bernkop-Schnurch A: The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release 52(1-2), 1-16 (1998).
27. Fix JA: Strategies for delivery of peptides utilizing absorption-enhancing agents. J. Pharm. Sci. 85(12), 1282-1285 (1996).
28. Leibach FH, Ganapathy V: Peptide transporters in the intestine and the kidney. Annu. Rev. Nutr. 16(1), 99-119 (1996).
29. Sundaram U, Wisel S, Coon S: Mechanism of inhibition of proton: dipeptide cotransport during chronic enteritis in the mammalian small intestine. Biochim. Biophys Acta 1714(2), 134-140 (2005).
30. Quintanar-Guerrero D, Allémann E, Fessi H. Doelker E: Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Pharm. Res. 14(2), 119-127 (1997).
31. Xin Hua Z: Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control Release 29(3), 239-252 (1994).
32. Salama NN, Eddington ND, Fasano A: Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58(1), 15-28 (2006).
33. Sharma P, Varma MVS, Chawla HPS, Panchagnula R: Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco 60(11-12), 884-893 (2005).
34. Foger F, Schmitz T, Bernkop-Schnurch A: In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27(23), 4250-4255 (2006).
35. Ambudkar SV, Kim I-W, Sauna ZE: The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur. J. Pharm. Biopharm. 27(5), 392-400 (2006).
36. Kim RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. 34(1-2), 47-54 (2002).
37. Ejendal KFK, Hrycyna CA: Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol. Pharmacol. 67(3), 902-911 (2005).
38. Yunomae K, Arima H, Hirayama F, Uekama K: Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 536(1-3), 225-231 (2003).
39. Oda M, Saitoh H, Kobayashi M, Aungst BJ: β-cyclodextrin as a suitable solubilizing agent for in situ absorption study of poorly water-soluble drugs. Int. J. Pharm. 280(1-2), 95-102 (2004).
40. Kreuter J: Nanoparticle-based drug delivery systems. J. Control. Release 16(1-2), 169-176 (1991).
41. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F: Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2(1), 8-21 (2006).
42. Allémann E, Gurny R, Doelker E: Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39(5), 173-191 (1993).
43. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55(3), 329-347 (2003).
44. Magenheim B, Benita S: Nanoparticle characterization: a comprehensive physicochemical approach. Stp Tharma Sci. 1(4), 221-241 (1991).
45. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE: Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70(1-2), 1-20 (2001).
46. Vauthier C, Dubernet C, Fattal E, Pinto-Andary H, Couvreur P: Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 55(4), 519-548 (2003).
47. Aguiar MMG, Rodrigues JM, Silva Cunha A: Encapsulation of insulin-cyclodextrin complex in PLGA microspheres: a new approach for prolonged pulmonary insulin delivery. J. Microencapsul. 21(5), 553-564 (2004).
48. Beletsi A, Panagi Z, Avgoustakis K: Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int. J. Pharm. 298(1), 233-241 (2005).
49. Duan Y, Sun X, Gong T, Wang Q, Zhang Z: Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitrol in vivo. J. Mater. Sci. Mater. Med. 17(6), 509-516 (2006).
50. Kang F, Jiang G, Hinderliter A, DeLuca PP, Singh J: Lysozyme stability in primary emulsion for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm. Res. 19(5), 629-633 (2002).
51. Koushik K, Dhanda D, Cheruvu N, Kompella U: Pulmonary delivery of deslorelin: large-porous PLGA particles and HPβCD complexes. Pharm. Res. 21(7), 1119-1126 (2004).
52. Li Y-P, Pei Y-Y, Zhang X-Y et al.: PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release 71(2), 203-211 (2001).
53. Quaglia F, De Rosa G, Granata E, Ungaro F, Fattal E, Immacolata La Rotonda M: Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying. J. Control. Release 86(2-3), 267-278 (2003).
54. Shakweh M, Besnard M, Nicolas V, Fattal E: Poly (lactide-co-glycotide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm. 61(1-2), 1-13 (2005).
55. Teixeira M, Alonso MJ: Pinto MMM, Barbosa CM: Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur. J. Pharm. Biopharm. 59(3), 491-500 (2005).
56. Zhang Z, Feng S-S: The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27(21), 4025-4033 (2006).
57. Nguyen CA, Allemann E, Schwach G, Doelker E, Gurny R: Cell interaction studies of PLA-MePEG nanoparticles. Int. J. Pharm. 254(1), 69-72 (2003).
58. Yi Y, Kim JH, Kang H-W, Oh HS, Kim SW, Seo MH: A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution. Pharm. Res. 22(2), 200-208 (2005).
59. Gao H, Yang YW, Fan YG, Ma JB: Conjugates of poly(dl-lactic acid) with ethylenediamino or diethylenetriamino bridged bis(β-cyclodextrin)s and their nanoparticles as protein delivery systems. J. Control. Release (2007) (In Press).
60. Sakuma S, Sudo R, Suzuki N et al.: Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. J. Control. Release 81(3), 281-290 (2002).
61. Norris DA, Puri N, Sinko PJ: The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 34(2-3), 135-154 (1998).
62. O'Hagan DT: Intestinal translocation of particulates - implications for drug and antigen delivery. Adv. Drug Deliv. Rev. 5(3), 265-285 (1990).
63. Jani PU, Florence AT, McCarthy DE: Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int. J. Pharm. 84(3), 245-252 (1992).
64. Ermak TH, Giannasca PJ: Microparticle targeting to M cells. Adv. Drug Deliv. Rev. 34(2-3), 261-283 (1998).
65. Gilligan CA, Li Wan Po A: Oral vaccines: design and delivery. Int. J. Pharm. 75(1), 1-24 (1991).
66. Jani PU, McCarthy DE, Florence AT: Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose. Int. J. Pharm. 86(2-3), 239-246 (1992).
67. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR: Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches. J. Control. Release 11(1-3), 205-214 (1990).
68. Owens DE III, Peppas NA: Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006).
69. Peracchia MT, Fattal E, Desmaele D et al.: Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60(1), 121-128 (1999).
70. Lemarchand C. Gref R. Couvreur P: Polysaccharide-decorated nanoparticies. Eur. J. Pharm. Biopharm. 58(2), 327-341 (2004).
71. Del Valle EMM: Cyclodextrins and their uses: a review. Process Biochem. 39(9), 1033-1046 (2004).
72. Szejtli J: Cyclodextrins properties and applications. Drug Invest. 2(S4), 11-21 (1990).
73. Thorsteinn L, Brewster ME: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85(10), 1017-1025 (1996).
74. Stella VJ, Rajewski RA: Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14(5), 556-567 (1997).
75. Challa R, Ahuja A. Ali J. Khar RK: Cyclodextrins in drug delivery: an updated review. AAPS Pharm Sci Tech. 6(2), E329-E357 (2005).
76. Li J, Xiao H, Li J, Zhong Y: Drug carrier systems based on water-soluble cationic β-cyclodextrin polymers. Int. J. Pharm. 278(2), 329-342 (2004).
77. Irie T, Uekama K: Cyclodextrins in peptide and protein delivery Adv. Drug Deliv. Rev. 36(1), 101-123 (1999).
78. Nagase Y, Hirata M, Arima H et al.: Protective effect of sulfobutyl ether β-cyclodextrin on DY-9760e-induced hemolysis in vitro. J. Pharm. Sci. 91(11), 2382-2389 (2002).
79. Hirayama F, Mieda S, Miyamoto Y, Arima H. Uekama K: Heptakis(2,6-di-O-methyl-3-[i O-acetyl)-β-cyclodextrin: a water-soluble cyclodextrin derivative with low hemolytic activity. J. Pharm. Sci. 88(10), 970-975 (1999).
80. Arima H. Yunomae K, Morikawa T, Hirayama F, Uekama K: Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm. Res. 21(4), 625-634 (2004).
81. Veiga F. Teixeira-Dias JJC, Kedzierewicz F. Sousa A, Maincent P: Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 129(1-2), 63-71 (1996).
82. Velga F, Fernandes C, Teixeira F: Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int. J. Pharm. 202(1-2), 165-171 (2000).
83. Radwan MA, Aboul-enein HY: The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J. Microencapsul. 19(2), 225-235 (2002).
84. Redenti E, Pietra C, Gerloczy A, Szente L: Cyclodextrins in oligonucleotide delivery. Adv. Drug Deliv. Rev. 53(2), 235-244 (2001).
85. Hirayama F, Uekama K: Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev. 36(1), 125-141 (1999).
86. Lin M, Jayawickrama DA, Rose RA, DelViscio JA. Larive CK: Nuclear magnetic resonance spectroscopic analysis of the selective complexation of the cis and trans isomers of phenylalanyiproline by β-cyclodextrin. Anal. Chim. Acta. 307(2-3), 449-457 (1995).
87. Aachmann FL. Otzen DE, Larsen KL, Wimmer R: Structural background of cyclodextrin-protein interactions. Protein Eng. 16(12), 905-912 (2003).
88. Angelova A. Ringard-Lefebvre C, Baszkin A: Drug-cyclodextrin association constants determined by surface tension and surface pressure measurements: I. host-guest complexation of water soluble drugs by cyclodextrins: polymyxin B-β cyclodextrin system. J. Colloid Interface Sci. 212(2). 275-279 (1999).
89. Camilleri P, Haskins NJ. Hewlett DR: β-Cyclodextrin interacts with the Alzheimer amyloid β-A4 peptide. FEBS Lett. 341(2-3), 256-258 (1994).
90. Garcia-Fuentes M, Trapani A, Alonso MJ: Protection of the peptide glutathione by complex formation with a-cyclodextrin: NMR spectroscopic analysis and stability study, Eur.J. Pharm. Biopharm. (2007) (In Press).
91. Kamphorst AO, Mendes de Sa I, Faria AM, Sinisterra RD: Association complexes between ovalbumin and cyclodextrins have no effect on the immunological properties of ovalbumin. Eur. J. Pharm. Biopharm. 57(2), 199-205 (2004).
92. Matilainen L, Jarvinen K, Toropainen T et al.: In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int. J. Pharm. 318(1-2), 41-48 (2006).
93. De Rosa G, Larobina D, La Rotonda MI, Musto P, Quaglia F, Ungaro, F: How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/ hydroxypropyl-β-cylodextrin system. J Control. Release 102(1), 71-83 (2005).
94. Junior JMR, de Melo Lima K, de Matos Jensen CE, de Agular MMG, da Silva Cunha Junior A: The effect of cyclodextrins on the in vitro and in vivo properties of insulin-loaded poly (D,L-lactic-coglycolic acid) microspheres. Artif. Organs 27(5). 492-497 (2003).
95. Castellanos IJ, Flores G, Griebenow K: Effect of cyclodextrins on a-chymotrypsin stability and loading in PLGA microspheres upon S/O/W encapsulation. J. Pharm. Sci. 95(4). 849-858 (2006).
96. Sigurjonsdottir JF, Loftsson T, Masson M: Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int. J. Pharm. 186(2). 205-213 (1999).
97. Kang F, Singh J: Conformational stability of a model protein (bovine serum albumin) during primary emulsification process of PLGA microspheres synthesis. Int. J. Pharm. 260(1), 149-156 (2003).
98. Jones IIG, Zhou X, Lu L: Inclusion by β-cyrlodextrin of a pyrene-labeled dipeptide photoprobe. Tetrahedron Lett. 43(34). 6079-6082 (2002).
99. Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R, Kawashima Y: Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with β-cyclodextrin. Eur. J. Pharm. Biopharm. 55(2), 147-154 (2003).
100. Yue IC, Poff J, Cortes ME et al.: A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease. Biomaterials 25(17), 3743-3750 (2004).
101. Duchene D, Ponchel G, Wouessidjewe D: Cyclodextrins in targeting: application to nanoparticies. Adv, Drug Deliv. Rev. 36(1), 29-40 (1999).
102. ane D: Combined Poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm. Res. 15(7), 1051-1055 (1998).
103. Maestrelli F, Garcia-Fuentes M, Mura P. Alonso MJ: A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin. Eur. J. Pharm. Biopharm. (2007) (in Press).
104. Vandervoort J, Ludwig A: Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur. J. Pharm. Biopharm. 57(2), 251-261 (2004).
105. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G: Combined hydroxypropyl-β-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended fbr oral administration of saquinavir. Int. J. Pharm. 218(1-2), 113-124 (2001).
106. Cavalli R, Peira E, Caputo O, Gasco MR: Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int. J. Pharm. 182(1), 59-69 (1999).
107. Utsuki T, Brem H, Pitha J et al.: Potentiation of anticancer effects of microencapsulated carboplatin by hydroxypropyl α-cyclodextrin. J. Control. Release 40(3), 251-260 (1996).
108. Gao H, Wang YN, Fan YG, Ma JB: Synthesis of a biodegradable tadpole-shaped polymer via the coupling reaction of polylactide onto mono(6-(2-aminoethyl)amino-6-deoxy)-β-cyclodextrin and its properties as the new carrier of protein delivery system. J. Control. Release 107(1), 158-173 (2005).
109. Duchene D, Wouessidjewe D, Ponchel G: Cyclodextrins and carrier systems. J. Control. Release 62(1-2), 263-268 (1999).
110. Jerry N, Anitha Y, Sharma CP, Poulose S: In vivo absorption studies of insulin from an oral delivery system. Drug Deliv. 8(1), 19-23 (2001).
111. I11 Bibby DC, Davies NM, Tucker IG: Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int. J. Pharm. 197(1-2), 1-11 (2000).
112. Memisoglu E, Bochot A, Sen M, Charon D, Duchêne D, Hincal AA: Amphiphilic β-cyclodextrins modified on the primary face: synthesis, characterization, and evaluation of their potential as novel excipients in the preparation of nanocapsules. J. Pharm. Sci. 91(5), 1214-1224 (2002).
113. Sallas F, Niikura K, Nishimura S-I: A practical synthesis of amphiphilic cyclodextrins fully substituted with sugar residues on the primary face. Chem. Commun. 5, 596-597 (2004).
114. Peroche S, Degobert G, Putaux J-L, Blanchin M-G, Fessi H, Parrot-Lopez H: Synthesis and characterisation of novel nanospheres made from amphiphilic perfluoroalkylthio-β-cyclodextrins. Eur. J. Pharm. Biopharm. 60(1), 123-131 (2005).
115. Liu Y, Yan-Li Zhao and Zhang H-Y: Recognition-induced supramolecular porous nanosphere formation from cyclodextrin conjugated by cholic acid langmuir. Langmuir, 22(7), 3434-3438 (2006).
116. Javierre I, Nedyalkov M, Petkova V et al.: Direct investigation of the vectorization properties of amphiphilic cyclodextrins in phospholipid films. J. Colloid Interface Sci. 254(1), 120-128 (2002).
117. Lahiani-Skiba M, Bounoure F, Shawky-Tous S, Arnaud P, Skiba M: Optimization of entrapment of metronidazole in amphiphilic β-cyclodextrin nanospheres. J. Pharm. Biomed. Anal. 41(3), 1017-1021 (2006).
118. Choisnard L, Gèze A, Putaux J-L, Wong Y-S, Wouessidjewe D: Nanoparticles of - cyclodextrin esters obtained by self-assembling of biotransesterified - cyclodextrins. Biomacromolecules 7(2), 515-520 (2006).
119. Choisnard L, Gèze A, Bigan M, Putaux J-L, Wouessidjewe D: Efficient size control of amphiphilic cyclodextrin nanoparticles through a statistical mixture design methodology. J. Pharm. Sci. 8(3), 593-600 (2005).
120. Geze A, Aous S, Baussanne I, Putaux J, Defaye J, Wouessidjewe D: Influence of chemical structure of amphiphilic β-cyclodextrins on their ability to form stable nanoparticles. Int. J. Pharm. 242(1-2), 301-305 (2002).
121. Gulik A, Delacroix H, Wouessidjewe D, Skiba M: Structural properties of several amphiphile cyclodextrins and some related nanospheres. An X-ray scattering and freeze-fracture electron microscopy study. Langmuir 14(5), 1050-1057 (1998).
122. Memisoglu-Bilensoy E, Dogan AL, Hincal AA: Cytotoxic evaluation of injectable cyclodextrin nanoparticles. J. Pharm. Pharmacol. 58(5), 585-598 (2006).
123. Memisoglu-Bilensoy E, Hincal AA: Sterile, injectable cyclodextrin nanoparticles: effects of γ irradiation and autoclaving. Int. J. Pharm. 311(1-2), 203-208 (2006).
124. Memisoglu-Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA: Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J. Control. Release 104(3), 489-496 (2005).
125. Sortino S, Mazzaglia A, Monsu Scolaro L, Marino Merlo F, Valveri V, Sciortino, MT: Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as carrier-sensitizer system in photodynamic cancer therapy. Biomaterials 27(23), 4256-4265 (2006).
126. Skiba M, Duchene D, Puisieux F, Wouessidjewe D: Development of a new colloidal drug carrier from chemically-modified cyclodextrins: nanospheres and influence of physicochemical and technological factors on particle size. Int. J. Pharm. 129(1-2), 113-121 (1996).
127. Skiba M, Morvan C, Duchene D, Puisieux F, Wouessidjewe D: Evaluation of gastrointestinal behaviour in the rat of amphiphilic β-cyclodextrin nanocapsules, loaded with indomethacin. Int. J. Pharm. 126(1-2), 275-279 (1995).
128. Falvey P, Woo C, Raphael L et al.: Bilayer vesicles of amphiphilic cyclodextrins: host membranes that recognize guest molecules. Chem. Eur. J. 11(4), 1171-1180 (2005).
129. Mazzaglia A, Angelini N, Darcy R et al.: Novel heterotopic colloids of anionic porphyrins entangled in cationic amphiphilic cyclodextrins: spectroscopic investigation and intracellular delivery. Chem. Eur. J. 9(23), 5762-5769 (2003).
130. Memisoglu E, Bochot A, Sen M, Duchene D, Hincal AA: Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic b-cyclodextrins. Int. J. Pharm. 251(1-2), 143-153 (2003).
131. Veiga MD, Ahsan F: Influence of surfactants (present in the dissolution media) on the release behaviour of tolbutamide from its inclusion complex with β-cyclodextrin. Eur. J. Pharm. Biopharm. 9(3), 291-299 (2000).
132. Memisoglu E, Bochot A, Özalp M, Sen M, duchene D, Hincal AA: Direct formation of nanospheres from amphiphilic β-cyclodextrin inclusion complexes. Pharm. Res. 20(1), 117-125 (2003).
133. Trapani G, Lopedota A, Boghetich G et al.: Encapsulation and release of the hypnotic agent zolpidem from biodegradable polymer microparticles containing hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 268(1-2), 47-57 (2003).